(r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias
F. Anthony Romero, Redwood City, CA (US); Thorsten A. Kirschberg, San Carlos, CA (US); Randall Halcomb, Foster City, CA (US); and Yingzi Xu, Palo Alto, CA (US)
Assigned to Terns Pharmaceuticals, Inc., Foster City, CA (US)
Filed by Terns Pharmaceuticals, Inc., Foster City, CA (US)
Filed on Mar. 6, 2025, as Appl. No. 19/072,824.
Application 19/041,557 is a division of application No. 18/339,516, filed on Jun. 22, 2023, granted, now 12,240,835, issued on Mar. 4, 2025.
Application 19/072,824 is a continuation of application No. 19/041,557, filed on Jan. 30, 2025.
Application 18/339,516 is a continuation of application No. 17/982,419, filed on Nov. 7, 2022, abandoned.
Application 17/982,419 is a continuation of application No. 17/711,894, filed on Apr. 1, 2022, abandoned.
Application 17/711,894 is a continuation of application No. 17/445,791, filed on Aug. 24, 2021, abandoned.
Application 17/445,791 is a continuation of application No. 17/145,163, filed on Jan. 8, 2021, abandoned.
Application 17/145,163 is a continuation of application No. 16/573,860, filed on Sep. 17, 2019, granted, now 10,889,571, issued on Jan. 12, 2021.
Claims priority of provisional application 62/889,929, filed on Aug. 21, 2019.
Claims priority of provisional application 62/816,637, filed on Mar. 11, 2019.
Claims priority of provisional application 62/733,029, filed on Sep. 18, 2018.
Prior Publication US 2025/0243184 A1, Jul. 31, 2025